---
title: "TriSalus Q2 FY26 net loss narrows 40.74% to $0.16 per share; revenue rises 1.7% to $11.4 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295138035.md"
description: "TriSalus Life Sciences reported Q2 FY26 revenue of $11.4 million, a 1.7% increase year-over-year. Net loss narrowed by 40.74% to $0.16 per share, down from $0.27, with total net loss at $9.2 million. However, operating loss widened to $9.8 million due to higher sales and marketing costs. Gross margin improved to 86.8%. The company maintained its full-year 2026 revenue guidance of $54-$57 million and held $46.3 million in cash."
datetime: "2026-08-06T20:11:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295138035.md)
  - [en](https://longbridge.com/en/news/295138035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295138035.md)
---

# TriSalus Q2 FY26 net loss narrows 40.74% to $0.16 per share; revenue rises 1.7% to $11.4 million

-   TriSalus Life Sciences posted Q2 revenue of $11.4 million, up 1.7% from the prior-year period. \* Operating loss widened to $9.8 million from $7.3 million, on higher sales and marketing costs tied to commercial expansion. \* Net loss available to common stockholders was $9.2 million; loss per share narrowed to $0.16 from $0.27. \* Gross margin rose 2.9 percentage points to 86.8%, due to a lower cost per TriNav unit. \* Maintained full-year 2026 revenue guidance of $54 million to $57 million; cash and cash equivalents were $46.3 million at June 30. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-054264), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TLSI.US](https://longbridge.com/en/quote/TLSI.US.md)
- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Analyst Justin Walsh Reaffirms Buy on TriSalus After Strong Q2 Results, CMS Reimbursement Tailwinds, and Growth Outlook Through 2026](https://longbridge.com/en/news/295431262.md)
- [TriSalus Leaders Quietly Make a Bold Bet on the Company’s Future](https://longbridge.com/en/news/286851061.md)
- [BRKR: Q2 2026 delivered strong revenue and EPS growth, with raised FY 2026 guidance](https://longbridge.com/en/news/294812512.md)
- [10:09 ETMGN Shareholder Alert: September 8, 2026 Lead Plaintiff Deadline in Megan Holdings Limited Securities Class Action - Contact SueWallSt](https://longbridge.com/en/news/295116232.md)
- [CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026](https://longbridge.com/en/news/295410054.md)